What Is the Expected Mounjaro® Weight Loss By Week?

Losing weight effectively and sustainably is a common goal for many individuals. With new advancements in medication, this journey has become more manageable. One such advancement is Mounjaro® (tirzepatide), a medication initially developed for type 2 diabetes that has shown significant promise in weight loss. In this article, we will explore how Mounjaro® works and what you can expect regarding weekly weight loss. We will also support these findings with clinical data.

Understanding Mounjaro® (Tirzepatide)

What Is Mounjaro®?

Mounjaro, also known as tirzepatide, is an injectable medication approved for managing type 2 diabetes. (1) However, its effectiveness in promoting weight loss has garnered much attention recently (2,3). Tirzepatide belongs to a class of medications called GLP-1 receptor agonists, which includes drugs like Semaglutide (Ozempic). These medications mimic the effects of the hormones GLP-1 and GIP, which regulate appetite and blood sugar levels.

How Does Mounjaro® Work for Weight Loss?

Tirzepatide aids weight loss through several mechanisms:

• Reducing Appetite: It signals the brain to feel full, reducing overall food intake (4,5).

• Slowing Gastric Emptying: This delay in digestion helps prolong the feeling of fullness (5).

• Improving Blood Sugar Control: Better management of blood sugar levels can contribute to reduced fat storage (5).

Expected Weight Loss With Mounjaro

Weekly Weight Loss Expectations

Clinical trials have demonstrated the effectiveness of Mounjaro® in supporting weight loss. Let’s break down the expected weekly weight loss:

• Initial Weeks (Weeks 1-4): During the first month, patients typically experience gradual weight loss as their bodies adjust to the medication. The average weight reduction is around 1-2 pounds per week (2).

• Long-Term Outcomes: Consistent use of Mounjaro® over a longer duration leads to substantial weight loss, which is demonstrated by various clinical trials. 

Throughout a 17-month clinical trial, overweight or obese individuals (average starting weight: 231 lbs) without diabetes who adhered to a reduced-calorie diet, increased physical activity, and used tirzepatide experienced sustained weight loss across all doses (5 mg, 10 mg, and 15 mg) (2).

• 5mg dose group: average weight loss was 15.0% (34 lbs) 

• 10mg dose group: 19.5% (44 lbs)

• 15mg dose group: 20.9% (48 lbs) 

• Placebo group: 3.1% (7 lbs) 

        (Jastreboff AM et al)

In another trial, randomized participants (who had similarly experienced an average weight decrease of 20.9% after 36 weeks of taking the maximum tolerated dose of tirzepatide (10 or 15 mg)) were split into two groups: those who continued taking tirzepatide and those who transitioned to a placebo (3). Those who transitioned to a placebo encountered a 14% weight regain, while those persisting with tirzepatide experienced an extra 5.5% weight reduction over the 52-week phase.

Comparing Tirzepatide to Semaglutide

To provide a comprehensive view, let's compare tirzepatide (Mounjaro) with another well-known GLP-1 receptor agonist, Semaglutide (Ozempic).

• Total Weight Loss: Both medications are effective – patients using Semaglutide have been shown to achieve an average of 14.9% total body weight reduction within 68 weeks (6).

• Efficacy: Studies indicate that tirzepatide may offer advantages over semaglutide. The The SURPASS-4 trial concluded that tirzepatide showed slightly superior results in both weight loss and blood sugar regulation (7).

Key Takeaways On Weight Loss With Mounjaro

Mounjaro® (tirzepatide) represents a promising option for those struggling with weight management. With an average weight loss of 1-3 pounds per week and the potential for significant long-term results, it offers hope for achieving healthier weight goals.

If you’re considering Mounjaro® or other weight loss medications, it is important to seek personalized advice from healthcare professionals. At Mochi Health, we offer tailored programs, virtual visits, and 24/7 support to help you achieve your health goals.

Call to Action

Discover if you're eligible for Mochi Health’s comprehensive weight care program today. Join tens of thousands nationwide who are taking control of their health with Mochi Health. Click here to get started.

‍

This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.

Sources

1. Anderson, S. L., & Marrs, J. C. (2023). Tirzepatide for type 2 diabetes. Drugs in context, 12, 2023-6-1. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/37664792/

2. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

3. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. https://jamanetwork.com/journals/jama/fullarticle/2812936

4. Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D'Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight, 5(17), e140532. https://doi.org/10.1172/jci.insight.140532

5. Urva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O'Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020). The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, obesity & metabolism, 22(10), 1886–1891. https://doi.org/10.1111/dom.14110

6. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://www.nejm.org/doi/10.1056/NEJMoa2032183?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

7. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K., & SURPASS-2 Investigators (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England journal of medicine, 385(6), 503–515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519